398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
About this episode
This episode discusses the acquisition of Kelonia Therapeutics and the strategies drugmakers are using to increase prescriptions through telehealth.
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion. We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.
People in this episode
Host: STAT
Guests: Bryan Roberts, Katie Palmer
Topics covered
- biotech acquisition
- CAR-T therapy
- drug prescriptions
- telehealth
- pharmaceutical strategies
- venture capital
Keywords
- biotech
- M&A
- telehealth
- drug sales
- CAR-T
- investment
- pharma
Mentioned in this episode
Organizations: Kelonia Therapeutics, Eli Lilly, Prescribery, STAT
More episodes of The Readout Loud
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
- 396: A new trick for old science, and biotech VCs' scrambled playbook
- 395: Biotech investors' plea to Trump, and a busy M&A week
- 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
- 393: A conversation with the 'godfather' of biotech
- 392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.